TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.26
+1.17%Aug 26, 2026, 11:30 UTC
Trevi Therapeutics announced that Professor Marlies Wijsenbeek will present quality-of-life outcomes from the Phase 2b CORAL trial of nalbuphine ER at the ERS Congress 2026.
Source:Aug 7, 2026, 18:05 UTC
Trevi Therapeutics began two clinical trials in Q2 2026 and plans to launch a third study in Q3 2026 for nalbuphine ER (Haduvio) in chronic-cough indications.
Source:Aug 6, 2026, 23:44 UTC
Trevi Therapeutics, Inc. held its Q2 2026 earnings call on August 6, 2026.
Source:Jun 4, 2026, 00:00 UTC
Michael Heffernan was elected as a Class I director of Trevi Therapeutics, Inc., effective June 3, 2026.